title: HIV and anal cancer outcomes: a single institution's experience.
abstract: OBJECTIVE
  The purpose of this study is to identify the effect of HIV status on outcome of treatment for squamous-cell carcinoma of the anal canal.
  
  
  METHODS
  A retrospective review was performed on all patients with squamous-cell carcinoma of the anal canal treated at a single academic institution between January 1996 and December 2006.
  
  
  RESULTS
  Our search identified 87 (21 HIV-positive) patients who had invasive squamous-cell cancer. The median follow-up was 38 months. Eighty-five percent of HIV-negative patients and 81 percent of HIV-positive were identified as complete responders at 6 weeks after completion of combined modality therapy. Eight percent of HIV-negative and 29 percent of HIV-positive patients developed recurrent disease after 6 months (P = 0.0009). Overall survival for HIV-negative and HIV-positive patients was 71 percent and 73 percent, respectively.
  
  
  CONCLUSIONS
  HIV-positive patients respond equally to combined modality therapy but have recurrences more frequently than patients who are HIV negative. Overall survival in these two groups is equivalent.
authors.affiliation: Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
authors.forename: Melissa E
authors.initials: ME
authors.lastname: Hogg
authors.forename: Daniel A
authors.initials: DA
authors.lastname: Popowich
authors.forename: Ed C
authors.initials: EC
authors.lastname: Wang
authors.forename: Kristina D
authors.initials: KD
authors.lastname: Kiel
authors.forename: Steven J
authors.initials: SJ
authors.lastname: Stryker
authors.forename: Amy L
authors.initials: AL
authors.lastname: Halverson
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001005:Anus Neoplasms / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D000069287:Capecitabine; D002294:Carcinoma, Squamous Cell / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000627:therapeutic use; D003125:Colostomy; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives / Q000627:therapeutic use; D015658:HIV Infections / Q000401:mortality*; D006801:Humans; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000627:therapeutic use; D008942:Mitoxantrone / Q000627:therapeutic use; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies
chemical_list: D000970:Antineoplastic Agents; D003841:Deoxycytidine; D016685:Mitomycin; D000069287:Capecitabine; D008942:Mitoxantrone; D002945:Cisplatin; D005472:Fluorouracil